4D Molecular Therapeutics (NASDAQ:FDMT) PT Raised to $58.00 at Jefferies Financial Group

4D Molecular Therapeutics (NASDAQ:FDMT) had its target price increased by equities research analysts at Jefferies Financial Group from $30.00 to $58.00 in a report released on Monday, Benzinga reports. The firm presently has a “buy” rating on the stock. Jefferies Financial Group’s price target points to a potential upside of 107.29% from the stock’s current price.

FDMT has been the topic of several other research reports. BMO Capital Markets increased their target price on 4D Molecular Therapeutics from $50.00 to $70.00 and gave the stock an “outperform” rating in a research report on Monday, February 5th. Royal Bank of Canada raised their price objective on 4D Molecular Therapeutics from $25.00 to $35.00 and gave the company an “outperform” rating in a research note on Monday, February 5th. The Goldman Sachs Group reiterated a “buy” rating and set a $81.00 target price on shares of 4D Molecular Therapeutics in a report on Wednesday, February 7th. Finally, HC Wainwright restated a “buy” rating and issued a $36.00 price objective on shares of 4D Molecular Therapeutics in a report on Friday, March 1st. One research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company. Based on data from MarketBeat.com, 4D Molecular Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $40.60.

4D Molecular Therapeutics Stock Performance

Shares of FDMT opened at $27.98 on Monday. The stock has a market capitalization of $1.39 billion, a price-to-earnings ratio of -10.52 and a beta of 2.87. 4D Molecular Therapeutics has a 52 week low of $9.44 and a 52 week high of $36.25. The stock has a fifty day moving average of $27.79 and a 200-day moving average of $19.10.

4D Molecular Therapeutics (NASDAQ:FDMT) last issued its earnings results on Thursday, February 29th. The company reported ($0.77) EPS for the quarter, missing the consensus estimate of ($0.68) by ($0.09). The firm had revenue of ($0.02) million during the quarter, compared to analyst estimates of $4.67 million. 4D Molecular Therapeutics had a negative net margin of 436.30% and a negative return on equity of 34.14%. As a group, equities analysts forecast that 4D Molecular Therapeutics will post -2.97 EPS for the current year.

Insider Buying and Selling at 4D Molecular Therapeutics

In other 4D Molecular Therapeutics news, insider Scott Bizily sold 5,833 shares of the stock in a transaction dated Wednesday, March 27th. The stock was sold at an average price of $35.04, for a total value of $204,388.32. Following the transaction, the insider now owns 1,737 shares of the company’s stock, valued at $60,864.48. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In other news, major shareholder Global Investors Lp Viking sold 540,000 shares of the firm’s stock in a transaction dated Thursday, January 4th. The stock was sold at an average price of $19.53, for a total value of $10,546,200.00. Following the transaction, the insider now owns 4,247,914 shares of the company’s stock, valued at $82,961,760.42. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Scott Bizily sold 5,833 shares of the firm’s stock in a transaction dated Wednesday, March 27th. The stock was sold at an average price of $35.04, for a total value of $204,388.32. Following the completion of the transaction, the insider now directly owns 1,737 shares in the company, valued at approximately $60,864.48. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 720,467 shares of company stock valued at $15,248,618. 10.70% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in FDMT. RA Capital Management L.P. grew its position in shares of 4D Molecular Therapeutics by 35.6% during the third quarter. RA Capital Management L.P. now owns 4,163,211 shares of the company’s stock worth $52,998,000 after purchasing an additional 1,093,680 shares in the last quarter. BlackRock Inc. grew its holdings in 4D Molecular Therapeutics by 14.3% during the 2nd quarter. BlackRock Inc. now owns 2,914,430 shares of the company’s stock valued at $52,664,000 after buying an additional 363,695 shares in the last quarter. State Street Corp grew its holdings in 4D Molecular Therapeutics by 0.4% during the 2nd quarter. State Street Corp now owns 2,050,430 shares of the company’s stock valued at $37,051,000 after buying an additional 8,241 shares in the last quarter. Novo Holdings A S grew its holdings in 4D Molecular Therapeutics by 25.0% during the 4th quarter. Novo Holdings A S now owns 1,500,000 shares of the company’s stock valued at $30,390,000 after buying an additional 300,000 shares in the last quarter. Finally, Vanguard Group Inc. grew its holdings in 4D Molecular Therapeutics by 0.6% during the 1st quarter. Vanguard Group Inc. now owns 1,290,941 shares of the company’s stock valued at $19,519,000 after buying an additional 7,858 shares in the last quarter. Institutional investors own 99.27% of the company’s stock.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.